Literature DB >> 12665475

VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease.

Yogesh Bangale1, Sangeeta Karle, Stephanie Planque, Yong-Xin Zhou, Hiroaki Taguchi, Yasuhiro Nishiyama, Lan Li, Ravishankar Kalaga, Sudhir Paul.   

Abstract

The immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) was cleaved by purified IgG from Fas-defective C3H/gld mice, lupus patients, and autoimmune thyroiditis patients. No VIPase activity was detected in IgG from control mice and humans. Kinetic analyses of VIPase IgG preparations suggested low-affinity recognition of VIP. Yet the VIPase activity was VIP selective, judged by lack of correlation with other protease activities expressed by the IgG and by noninterference of unrelated peptides in the activity. Recombinant Fv constructs selected from a human lupus phage show library displayed VIPase activity, confirming that the active site is located in the V domains. Inhibition of the VIPase activity by di-isopropylfluorophosphate suggested a serine protease-like mechanism of catalysis. Irreversible binding of a biotinyated phosphonate diester by the IgG and Fv preparations was observed, consistent with the presence of activated nucleophiles similar to those in enzymes capable of covalent catalysis. These observations show that VIP is a target for specific catalytic autoantibodies in autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665475     DOI: 10.1096/fj.02-0475com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

2.  Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.

Authors:  Eric L Brown; Yasuhiro Nishiyama; Jesse W Dunkle; Shreya Aggarwal; Stephanie Planque; Kenji Watanabe; Keri Csencsits-Smith; M Gabriela Bowden; Sheldon L Kaplan; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

3.  Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.

Authors:  Alejo Chorny; Elena Gonzalez-Rey; Amelia Fernandez-Martin; David Pozo; Doina Ganea; Mario Delgado
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

Review 4.  Antibodies as defensive enzymes.

Authors:  Sudhir Paul; Yasuhiro Nishiyama; Stephanie Planque; Sangeeta Karle; Hiroaki Taguchi; Carl Hanson; Marc E Weksler
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

Review 5.  Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Authors:  Mario Delgado; Doina Ganea
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

Review 6.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.

Authors:  D Ganea; K M Hooper; W Kong
Journal:  Acta Physiol (Oxf)       Date:  2014-12-11       Impact factor: 6.311

Review 7.  Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

Authors:  David Pozo; Elena Gonzalez-Rey; Alejo Chorny; Per Anderson; Nieves Varela; Mario Delgado
Journal:  Peptides       Date:  2007-04-20       Impact factor: 3.750

Review 8.  Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.

Authors:  Elena Gonzalez-Rey; Per Anderson; Mario Delgado
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

9.  Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Yukie Mitsuda; Giovanni Nitti; Hiroaki Taguchi; Lei Jin; Jindrich Symersky; Stephane Boivin; Marcin Sienczyk; Maria Salas; Carl V Hanson; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

Review 10.  Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.

Authors:  Per Anderson; Mario Delgado
Journal:  J Cell Mol Med       Date:  2008-06-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.